Join to view full profile
55 Fruit StYawkey 9ABoston, MA 02114
Phone+1 617-724-4000
Dr. Yee is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Andrew J. Yee is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Massachusetts General Hospital and North Shore Medical Center. He is an Assistant Professor of Medicine at Harvard Medical School. He received his medical degree from Harvard Medical School and has been in practice 17 years. He specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2004 - 2007
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2000 - 2003
Harvard Medical SchoolClass of 2000
Certifications & Licensure
MA State Medical License 2002 - 2028
NH State Medical License 2009 - 2027
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Longitudinal Medical Record, Partners Healthcare System, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2012, 2014, 2016-2017
Clinical Trials
Publications & Presentations
PubMed
- Long-term outcomes of modified-intensity lenalidomide, bortezomib and dexamethasone (RVD-lite) in transplant-ineligible multiple myeloma: final report of a phase II tr...Joshua N Gustine, Elizabeth K O'Donnell, Jacob P Laubach, Andrew J Yee, Carol Ann Huff
Clinical Cancer Research. 2026-10-05 - Toward a Cure in Multiple Myeloma: Redefining Induction Therapy and the Role of Autologous Stem Cell Transplant.Advait Joshi, Benjamin R Puliafito, Diana D Cirstea, Andrew R Branagan, Joshua N Gustine
Cancer Journal. 2026-09-25 - 1 citationsCharacterization of Hypogammaglobulinemia, Infection Incidence, and Mortality in Patients Receiving B-cell Maturation Antigen Chimeric Antigen Receptor (CAR) T-cell Th...Katherine J Liu, Lingxiao Zhang, Baijun Zhou, Joseph S Hong, Andrew Pak
Transplantation and Cellular Therapy. 2026-09-01
Lectures
- Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Analysis of Hospitalization and Readmissions after CAR T Cell Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Year in Review: Multiple MyelomaNovember 3rd, 2025- Multiple Myeloma: Novel Quad Regimen Eases ToxicitySeptember 24th, 2025
- Upcoming Alliance Webinar Showcases Cutting-Edge Advances in Cancer TreatmentFebruary 27th, 2026
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: